KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Operating Leases (2019 - 2021)

Historic Operating Leases for Abbott Laboratories (ABT) over the last 3 years, with Q4 2021 value amounting to $956.0 million.

  • Abbott Laboratories' Operating Leases rose 598.67% to $956.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $956.0 million, marking a year-over-year increase of 598.67%. This contributed to the annual value of $956.0 million for FY2021, which is 598.67% up from last year.
  • Abbott Laboratories' Operating Leases amounted to $956.0 million in Q4 2021, which was up 598.67% from $902.0 million recorded in Q4 2020.
  • Over the past 5 years, Abbott Laboratories' Operating Leases peaked at $956.0 million during Q4 2021, and registered a low of $755.0 million during Q4 2019.
  • Moreover, its 3-year median value for Operating Leases was $902.0 million (2020), whereas its average is $871.0 million.
  • Per our database at Business Quant, Abbott Laboratories' Operating Leases soared by 1947.02% in 2020 and then surged by 598.67% in 2021.
  • Quarter analysis of 3 years shows Abbott Laboratories' Operating Leases stood at $755.0 million in 2019, then grew by 19.47% to $902.0 million in 2020, then increased by 5.99% to $956.0 million in 2021.
  • Its Operating Leases was $956.0 million in Q4 2021, compared to $902.0 million in Q4 2020 and $755.0 million in Q4 2019.